Company Overview
ImmuCell Corporation functions as an animal health enterprise focused on the development, manufacturing, and sale of products designed to enhance the health and productivity of dairy and beef cattle markets within the United States and internationally. The company operates specifically within the healthcare sector, with its core business activities falling under the biotechnology industry, which implies a focus on scientific innovation and specialized biological solutions for agricultural applications. The firm's current market capitalization stands at $58.98M, supported by an annual revenue of $27.64M, while the employee count is listed as N/A in available records. These valuation and revenue figures indicate that ImmuCell Corporation occupies a small-cap position in the broader healthcare landscape, suggesting a niche market presence rather than mass-market dominance. The specific focus on two operational segments, Scours and Mastitis, further delineates its specialized role in addressing specific veterinary challenges for livestock producers.
Financial Health
ImmuCell Corporation reported a trailing twelve-month revenue of $27.64M alongside a net income loss of $-1,040,000, and an EBITDA of $4.35M, revealing a distinct gap between top-line generation and bottom-line profitability that points to significant operating expenses or non-operating costs eroding earnings. The free cash flow is listed as N/A, which prevents a direct assessment of immediate financial flexibility but suggests that cash conversion from operations may be constrained by the company's current burn rate or capital expenditure cycles. Analysis of the margin structure shows a gross margin of 41.4%, indicating reasonable efficiency in production and supply chain management before operating expenses are deducted. However, the operating margin stands at -0.8% and the profit margin is -3.8%, signaling that high operating costs or general administrative expenses are currently outweighing gross profits to the point of overall unprofitability. The company holds $3.89M in cash against $13.61M in debt, resulting in a debt-to-equity ratio of 45.66, which characterizes the balance sheet as highly leveraged given the substantial debt obligation relative to equity and cash reserves. While the current ratio is listed as N/A, preventing a specific liquidity assessment, the negative net income and high debt levels suggest that short-term liquidity management requires careful attention to cash flow generation. Return on Equity is recorded at -3.6% and Return on Assets is N/A, metrics that collectively reveal that management has not yet achieved positive returns on shareholder capital or total assets, reflecting the challenges of the current operational phase.
Valuation Assessment
The trailing P/E ratio is listed as N/A due to the net loss, while the forward P/E is reported at -59.27, a negative figure that implies analysts are projecting continued earnings losses in the near term rather than an immediate turnaround in profitability. The price-to-book ratio is 1.98, suggesting that the market values the company at nearly double its book value, which may indicate expectations of future intangible asset appreciation or successful product adoption despite current losses. Alternative valuation metrics such as the price-to-sales ratio of 2.13 and an EV/EBITDA of 15.80 provide perspective on the company's valuation relative to its revenue and earnings before interest, taxes, depreciation, and amortization, though the negative earnings complicate the interpretation of the EV/EBITDA multiple in a traditional sense. The stock's trading range over the past year spans a high of $7.60 and a low of $4.52, and based on the provided data points, the current price sits within this historical band, reflecting market volatility typical for small-cap biotechnology stocks. The beta value is 0.30, which indicates that the stock's price volatility is significantly lower than the broader market, suggesting it may be less sensitive to general market swings but potentially subject to higher idiosyncratic risk associated with its specific business model.
Growth & Income
ImmuCell Corporation recorded a revenue growth rate of -1.6% year-over-year, while earnings growth is listed as N/A due to the negative earnings baseline, indicating that the company is currently contracting in terms of sales rather than expanding its top line. The absence of positive earnings growth relative to the declining revenue suggests that the company is struggling to maintain market share or pricing power in a competitive animal health environment. As a non-dividend payer, the company does not distribute a dividend yield or operates with a payout ratio of 0.0%, meaning it retains all earnings to reinvest into research, development, and manufacturing capabilities rather than returning capital to shareholders. Consequently, the overall growth and income profile is defined by revenue contraction and a reliance on retained earnings for future operational scaling, rather than providing current income through dividends or consistent earnings expansion.